Direct Oral Anticoagulants vs Vitamin K Antagonists in Patients With Antiphospholipid Syndromes: Meta-Analysis of Randomized Trials

Journal of the American College of Cardiology
Review (4 open-label RCTs; n= 472) found an increased risk in the composite of arterial thrombotic events or VTE with DOACs vs VKAs (OR: 4.46; 95% CI: 1.12-17.84; P = 0.03) but no difference in subsequent VTE (1.20; 0.31-4.55) or major bleeding (1.02; 0.42-2.47).